1. Scrip
  2. >>Focus On Asia
  3. >>China

Pfizer Bets $480m On CStone And Surging China Immuno-Oncology Market

26% Annual IO Growth Forecast Alluring

 
• By Brian Yang

The latest big pharma vote of confidence in both the China market and R&D capabilities comes amid continuing standoffs with the US over a flurry of issues including the coronavirus, national security and trade, but as the pandemic seemingly recedes in China.

CSTONE SIGNS ON PFIZER TO COMMERCIALIZE ITS PD-L1 TO CAPTURE CHINA GROWTH • Source: Shutterstock

Right before China’s mid-autumn festival, a traditional time to celebrate harvest time, a major deal between a Chinese drug developer and a global pharma giant put the spotlight on the country’s rebounding health market post COVID-19.

Shanghai-based CStone Pharmaceuticals Co. Ltd., an oncology specialist founded four years ago, announced on 29 September a collaboration under which Pfizer Inc

More from China

More from Focus On Asia